While DAPA-HF showed reductions in both NT-proBNP and adverse HF outcomes in patients treated with dapagliflozin, the DEFINE-HF trial showed improvement in HF symptoms but not in NT-proBNP levels [158,200]. The gene discussed is NPPB; the disease is hydrops fetalis.